|
| |
Acorda TherapeuticsAcorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial development efforts on a range of therapeutics for individuals with chronic, or long term, SCI. Currently, there is no therapy that improves neurological function in chronic SCI patients.
However, Acorda's clinical stage product, Fampridine-SR, has improved neurological function for patients with chronic SCI in Phase 2 clinical trials. The Company believes that the therapeutic products it develops for SCI are likely also to have applications in other neurological conditions-for example, both Fampridine-SR and the Company's M1 monoclonal antibody ("M1") product have shown promise as therapies for multiple sclerosis ("MS"). Other potential markets for the Company's products include traumatic brain injury, Parkinson's disease and stroke.
| Contact Details: |
| 15 Skyline Drive |
| Hawthorn |
| |
| 10532 |
| United States of America |
| Tel: | 914-347-4300 |
| Fax: | 914-347-4560 |
| Email: | info@acorda.com |
| WWW: | www.acorda.com/
|
| |
Recent Publications by Acorda Therapeutics: |  |
Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.
BACKGROUND: Tizanidine is an imidazoline with central... | 3rd November, 2009
| Medical Affairs Department, Acorda Therapeutics, Inc., Hawthorne, New
| Paediatr Drugs. 2009;11(6):397-406. doi: 10.2165/11316090-000000000-00000.
DOI Direct Link |
Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
BACKGROUND: Fampridine (4-aminopyridine) is a potassium channel blocker... | 13th May, 2009
| Acorda Therapeutics, Hawthorne, New York, USA.
| Clin Ther. 2009 Feb;31(2):328-35.
DOI Direct Link |
Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
BACKGROUND: The alpha2-adrenergic agonist tizanidine has been reported to... | 20th March, 2009
| Acorda Therapeutics, Inc., Hawthorne, New York 10532, USA.
| Clin Ther. 2008 Dec;30(12):2263-71.
DOI Direct Link |
A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
AIMS: Tizanidine, one of the few oral antispastic therapies approved for... | 1st August, 2008
| Medical Affairs Department, Acorda Therapeutics, Inc., Hawthorne, NY, USA.
| Int J Clin Pract. 2008 Feb;62(2):314-24.
DOI Direct Link |
Chondroitin sulfate proteoglycans in spinal cord contusion injury and the effects of chondroitinase treatment.
Chondroitinase treatment of experimental spinal cord injury improves... | 28th February, 2008
| Acorda Therapeutics, Inc., Hawthorne, New York 10532, USA.
| J Neurotrauma. 2007 Nov;24(11):1743-59.
DOI Direct Link |
→View more Acorda Therapeutics research publications. |
Press Releases on Acorda Therapeutics:
|
 |
| Reportlinker Adds World Neurodegenerative Diseases Market 2009-2024 |
3rd November, 2009 |
Reportlinker |
-- Rilutek.
In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments.
Detailed analysis of the
|
| I Walk Because Program Gives Consumers a Voice |
18th June, 2009 |
Saatchi & Saatchi Wellness |
- Provide Rich Social Media Experience For WalkMS Participants -
NEW YORK, June 18 /PRNewswire/ -- Reinforcing its commitment to those who support friends, family, and other people living with
|
| United Spinal Association's 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities |
18th May, 2009 |
United Spinal Association |
NEW YORK, May 18 /PRNewswire-USNewswire/ -- The 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities, a unique gathering to promote an exchange of ideas
|
| Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer |
2nd September, 2008 |
Micromet, Inc. |
BETHESDA, Md., Sept. 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:
MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing
novel, proprietary
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1386 times since April 2007, the link to the organisation's website has been followed 201 times Recent Search Terms used to find this page: acorda therapeutics background | acorda therapeutics inc. background | acorda Therapeutics*Hawthorne NY*USA | position statement on the sale of unproven cellular therapies for spinal cord injury | M1 antibody spinal cord injury trial acorda | accorda hawthorne | monoclonal antibody m1 acorda | acorda therapeutics | 4-aminopyridine multiple sclerosis patent | accorda | . Search for more companies in Hawthorn Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Acorda Therapeutics |
